BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 MARCH 2011 at 1.30 pm Not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or South Africa. New Biotie shares and increase of share capital registered with the trade register A total of 35,230,000 new shares offered in Biotie Therapies Corp.'s ("Biotie") directed share issue announced on 11 March 2011 and the share capital increase of EUR 26,987,625.36 related to the new shares and the sale of the treasury shares have been registered with the Finnish Trade Register today on 18 March 2011. The registered new shares are expected to be traded together with the current Biotie shares on the stock exchange list of NASDAQ OMX Helsinki Ltd as of 21 March 2011. The new shares entitle to shareholder rights as of the registration date of 18 March 2011. After the registration of the new shares with the Finnish Trade Register and the registration of the share capital increase, the share capital of Biotie is EUR 165,919,181.95 and the total number of shares 387,594,457. Since 14,912,155 Biotie shares are held by Biotie and its subsidiaries, the number of votes outstanding amounts to 372,682,302. In Turku, 18 March 2011 Biotie Therapies Corp. Timo Veromaa, President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media The information herein may not be distributed or sent into the United States, Australia, Canada, Japan or South Africa. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. The information contained herein does not constitute an offer of securities for sale in the United States. The securities referenced in this release may not be offered or sold in the United States absent registration or an exemption from registration as provided in the United States Securities Act of 1933, as amended, and the rules and regulations thereunder. Biotie does not intend to register any portion of the Offering in the United States or to conduct a public offering of any securities in the United States. No securities will be offered or sold in any Member State of the European Economic Area other than to persons who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive. For the purposes of this provision, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression "2010 Amending Directive" means Directive 2010/73/EU. This communication does not constitute an offer of securities to the public in the United Kingdom. This communication is directed only at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FP Order") and (iii) high net worth entities falling within Article 49(2) of the FP Order, and other persons to whom it may lawfully be communicated, (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to, and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Nordea Bank Finland Plc ("Nordea") and Nomura Code Securities Limited ("Nomura") are acting exclusively for Biotie and no one else in connection with the Offering. They will not regard any other person (whether or not a recipient of this release) as their client and will not be responsible to anyone other than Biotie for providing the protections afforded to their clients, nor for giving advice in relation to the Offering or any transaction or arrangement referred to herein. No representation or warranty, express or implied, is made by Nordea or Nomura as to the accuracy, completeness or verification of the information set forth in this release. [HUG#1497998]
New Biotie shares and increase of share capital registered with the trade register
| Source: Biotie Therapies